Can-Fite Biopharma Ltd Sponsored ADR (Israel)

1.73-0.0100-0.57%Vol 99.48K1Y Perf -8.99%
Sep 15th, 2021 16:00 DELAYED
BID1.72 ASK1.73
Open1.73 Previous Close1.74
Pre-Market- After-Market-
 - -%  - -
Target Price
5.00 
Analyst Rating
Strong Buy 1.00
Potential %
189.02 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     46.35
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
3.27 
Earnings Rating
Strong Sell
Market Cap33.03M 
Earnings Date
26th Aug 2021
Alpha-0.05 Standard Deviation0.19
Beta1.94 

Today's Price Range

1.711.77

52W Range

1.644.39

5 Year PE Ratio Range

-4.50-1.20

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-2.81%
1 Month
-9.42%
3 Months
-28.22%
6 Months
-40.75%
1 Year
-8.99%
3 Years
-91.20%
5 Years
-95.01%
10 Years
-

TickerPriceChg.Chg.%
CANF1.73-0.0100-0.57
AAPL149.030.91000.61
GOOG2 904.1236.00001.26
MSFT304.825.03001.68
XOM56.421.84003.37
WFC46.640.59001.28
JNJ165.420.62000.38
FB373.92-2.6100-0.69
GE102.161.78001.77
JPM158.161.09000.69
Financial StrengthValueIndustryS&P 500US Markets
4.00
4.00
0.01
0.02
-51.00
Leverage Ratio 1.70
ProfitabilityValueIndustryS&P 500US Markets
-
-1 485.80
-1 483.90
-1 537.10
-
RevenueValueIndustryS&P 500US Markets
759.00K
0.04
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.12-0.19-58.33
Q01 2021-0.17-0.1229.41
Q04 2020-0.13-0.30-130.77
Q03 2020-0.25-0.244.00
Q02 2020-0.28-0.30-7.14
Q01 2020-0.59-0.72-22.03
Q04 2019-0.89-0.6032.58
Q03 2019-0.58-0.90-55.17
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.140.00-
12/2021 QR-0.16-14.29Negative
12/2021 FY-0.55-12.24Negative
12/2022 FY-0.390.00-
Next Report Date-
Estimated EPS Next Report-0.12
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume99.48K
Shares Outstanding19.09M
Shares Float19.09M
Trades Count195
Dollar Volume1.84M
Avg. Volume1.64M
Avg. Weekly Volume84.95K
Avg. Monthly Volume154.46K
Avg. Quarterly Volume207.62K

Can-Fite Biopharma Ltd Sponsored ADR (Israel) (AMEX: CANF) stock closed at 1.73 per share at the end of the most recent trading day (a -0.57% change compared to the prior day closing price) with a volume of 107.37K shares and market capitalization of 33.03M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 8 people. Can-Fite Biopharma Ltd Sponsored ADR (Israel) CEO is Pnina Fishman.

The one-year performance of Can-Fite Biopharma Ltd Sponsored ADR (Israel) stock is -8.99%, while year-to-date (YTD) performance is -2.81%. CANF stock has a five-year performance of -95.01%. Its 52-week range is between 1.64 and 4.39, which gives CANF stock a 52-week price range ratio of 3.27%

Can-Fite Biopharma Ltd Sponsored ADR (Israel) currently has a PE ratio of -5.90, a price-to-book (PB) ratio of 8.59, a price-to-sale (PS) ratio of 44.77, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -97.51%, a ROC of -170.81% and a ROE of -166.04%. The company’s profit margin is -%, its EBITDA margin is -1 483.90%, and its revenue ttm is $759.00 Thousand , which makes it $0.04 revenue per share.

Of the last four earnings reports from Can-Fite Biopharma Ltd Sponsored ADR (Israel), there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.12 for the next earnings report. Can-Fite Biopharma Ltd Sponsored ADR (Israel)’s next earnings report date is -.

The consensus rating of Wall Street analysts for Can-Fite Biopharma Ltd Sponsored ADR (Israel) is Strong Buy (1), with a target price of $5, which is +189.02% compared to the current price. The earnings rating for Can-Fite Biopharma Ltd Sponsored ADR (Israel) stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Can-Fite Biopharma Ltd Sponsored ADR (Israel) has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Can-Fite Biopharma Ltd Sponsored ADR (Israel) has a Sell technical analysis rating based on Technical Indicators (ADX : 30.52, ATR14 : 0.08, CCI20 : -148.82, Chaikin Money Flow : -0.03, MACD : -0.07, Money Flow Index : 29.50, ROC : -7.73, RSI : 31.47, STOCH (14,3) : 9.09, STOCH RSI : 0.17, UO : 35.52, Williams %R : -90.91), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Can-Fite Biopharma Ltd Sponsored ADR (Israel) in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is a clinical-stage biopharmaceutical company. The company is focused on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune inflammatory indications, oncology and liver diseases as well as sexual dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention. The company's pipeline drugs are synthetic, specific agonists and allosteric modulators targeting the A3AR. All drugs are orally bioavailable with an excellent safety profile.

CEO: Pnina Fishman

Telephone: +972 39241114

Address: 10 Bareket Street, Kiryat Matalon, Petah-Tikva 4951778, , IL

Number of employees: 8

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

63%38%

Bearish Bullish

53%47%

News

Stocktwits